Work

146TiP This abstract has been removed because it was not presented at the European Lung Cancer Congress 2026

Year: 2026

Type: article

Abstract: Zelenectide pevedotin (zele; formerly BT8009) is a Bicycle® Drug Conjugate (BDC®) comprising a highly selective bicyclic peptide targeting Nectin-4 linked to MMAE via a cleavable linker. With low molecular weight and short plasma half-life, zele has potential to rapidly penetrate solid tumours with minimal exposure to healthy tissue. The ongoing phase I/II Duravelo-1 trial (NCT04561362; BT8009-100) has shown preliminary antitumour activity and a manageable safety profile of zele monotherapy in patients (pts) with NSCLC.

Source: ESMO Open

DOI: 10.1016/j.esmoop.2026.106453